Stryker (SYK) announced that its OptaBlate basivertebral nerve ablation system received 510(k) clearance from the Food and Drug Administration. OptaBlate BVNA is used in a targeted minimally invasive procedure providing vertebrogenic pain relief, the company said in a statement. “The addition of the OptaBlate BVN to Stryker’s pain portfolio expands its advanced pain therapy solutions for patients and is an intersection of its two core competencies: radiofrequency ablation technology and vertebral access,” it added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker Shareholders Approve Amendments at Annual Meeting
- Stryker’s Strategic Moves and Strong Financial Outlook Justify Buy Rating with $435 Price Target
- Stryker price target raised to $400 from $390 at Truist
- Stryker price target raised to $450 from $440 at Bernstein
- Stryker’s Strong Performance and Growth Potential Justify Buy Rating